89bio

89bio

Biotechnology, 142 Sansome St, San Francisco, California, 94104, United States, 11-50 Employees

89bio.com

  • facebook
  • LinkedIn

phone no Phone Number: 51********

Who is 89BIO

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The ...

Read More

map
  • 142 Sansome St, San Francisco, California, 94104, United States Headquarters: 142 Sansome St, San Francisco, California, 94104, United States
  • 2018 Date Founded: 2018
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from 89BIO

89bio Org Chart and Mapping

Employees

Cindy Hartsfield

Director Medical Affairs

Leo Tseng

Executive Director of Clinical Pharmacology

Michael Baldwin

Vice President Quality Assurance

Jyoti Chauhan

Vice President Regulatory Affairs

Emily Hester

Senior Director Clinical Quality Assurance

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding 89bio

Answer: 89bio's headquarters are located at 142 Sansome St, San Francisco, California, 94104, United States

Answer: 89bio's phone number is 51********

Answer: 89bio's official website is https://89bio.com

Answer: 89bio's revenue is $5 Million to $10 Million

Answer: 89bio's SIC: 2834

Answer: 89bio has 11-50 employees

Answer: 89bio is in Biotechnology

Answer: 89bio contact info: Phone number: 51******** Website: https://89bio.com

Answer: 89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The companys lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Recent Phase 1b/2a data show BIO89-100 demonstrated a favorable safety and tolerability profile and robust reductions in liver fat and key lipid markers when dosed weekly or once every two weeks in patients with NASH. BIO89-100 is currently in a Phase 2 trial for the treatment of SHTG. 89bio is headquartered in San Francisco with operations in Herzliya, Israel. Our culture is best described by our values: Always putting the patient first Operating with the highest integrity and ethical standards at all times Being authentic in all our transactions Acting as a team collaborating, respecting and caring for one another Being entrepreneurial and passionate in our tasks Being scientific and rational in our thought process and decision-making

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access